SCHEDULE: Baselake Partners Reports 6.8% Stake in TherapeuticsMD

Baselake Partners, LP, along with its affiliates Baselake Management, LLC and David Paolella, has filed a Schedule 13G, confirming beneficial ownership of 790,703 shares, representing 6.8% of TherapeuticsMD, Inc.'s common stock.

Summary

• Baselake Partners, LP, Baselake Management, LLC, and David Paolella (collectively, the 'Reporting Persons') have filed an amended Schedule 13G.
• The filing confirms their beneficial ownership of 790,703 shares of TherapeuticsMD, Inc. common stock.
• This ownership stake represents 6.8% of the total outstanding shares.
• The shares are held directly by Baselake Partners, LP, with Baselake Management, LLC acting as the investment manager and David Paolella as the managing member of the investment manager.
• The filing states that the Reporting Persons may be deemed to have shared voting and dispositive power over these shares.
• The percentage is calculated based on 11,574,362 shares outstanding as of May 11, 2026, according to the Issuer's 10-Q.
• The Reporting Persons disclaim beneficial ownership beyond their pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not dominant ownership stake by Baselake Partners, LP and its affiliates. The filing primarily confirms an existing ownership level rather than announcing a new development.

Positives

• Confirmation of a substantial ownership stake (6.8%) by an investment entity, which can signal confidence in the company's prospects.
• The filing is an amendment, suggesting a routine update rather than a new, potentially disruptive event.

Negatives

• The filing does not indicate any new investment or increase in stake, suggesting a static position.
• The disclaimer of beneficial ownership beyond pecuniary interest is a standard but cautious statement.

Risks

• The filing does not explicitly mention any new risks or challenges faced by TherapeuticsMD, Inc.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from TherapeuticsMD, Inc. It is a disclosure of ownership.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in public companies. This filing indicates Baselake Partners, LP's continued interest in TherapeuticsMD, Inc. as a substantial shareholder.

Stakeholder Impact

• Shareholders: The filing confirms a significant ownership stake, which may be viewed positively by some shareholders as an indication of institutional support, but it does not represent a change in control or a new investment.
• Management: The filing is a routine disclosure and does not directly impact management's operational decisions, but it confirms the presence of a significant institutional investor.
• Creditors: No direct impact is indicated.

Next Steps

• The Reporting Persons will continue to monitor their investment in TherapeuticsMD, Inc.

Key Dates

Keywords

TherapeuticsMD, Baselake Partners, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Shareholder